<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307749</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-257-A03</org_study_id>
    <nct_id>NCT00307749</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the efficacy and safety of three doses of
      MCC-257 in patients with mild to moderate diabetic polyneuropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use a double-blind, randomized, placebo-controlled, fixed-dose, parallel-group
      design. Patients will be randomized equally to 1 of 4 treatment groups: MCC-257 20 mg,
      MCC-257 40 mg, MCC-257 80 mg, or placebo, given once daily for 24 weeks. The study will
      consist of 2 periods: 1) a screening period of up to 21 days prior to baseline, including a
      formal screening visit; and 2) a 24-week treatment period, during which patients will take
      the study treatment, and have various assessments performed during 4 visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve Conduction Studies</measure>
    <time_frame>Day 1, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nerve fiber density</measure>
    <time_frame>Day 1, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QST</measure>
    <time_frame>Day 1, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom</measure>
    <time_frame>Day 1, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>Week 12, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCC-257</intervention_name>
    <description>20mg, once daily for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCC-257</intervention_name>
    <description>40mg, once daily for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCC-257</intervention_name>
    <description>80mg, once daily for 24 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is male or female, 18-70 years of age

          -  The patient has either type 1 or type 2 diabetes

          -  The patient has mild to moderate diabetic neuropathy

          -  The patient is free from other clinically significant illness or disease, as
             determined by medical history, physical examination, laboratory evaluations, and other
             safety tests

        Exclusion Criteria:

          -  Being treated with anticoagulants other than aspirin, such as warfarin, digoxin,
             Plavix

          -  BMI&gt;40

          -  A significant disorder or a condition other than diabetes that can cause symptoms or
             physical conditions that mimic peripheral neuropathy or interfere with cognition

          -  Any proximal neuropathy, clinically evident nerve entrapment, or any focal trauma
             potentially affecting nerve function

          -  Women of childbearing potential who do not refrain from sexual activity or use
             adequate contraception

          -  Pregnant or lactating women

          -  An ALT or AST value &gt;2X upper limit of normal (ULN)

          -  Clinically significant cardiovascular disease within the last six (6) months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Information at Mitsubishi Pharma America</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2007</last_update_posted>
  <keyword>Neuropathy</keyword>
  <keyword>Nerve Conduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

